Prosecution Insights
Last updated: November 12, 2026

BPGbio, Inc.

Technology areas: Biotechnology & Pharmaceuticals • Transportation, E-Commerce & Mechanical Systems

5 pending office actions • 5 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days

Analysis

BPGbio, Inc. has 5 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 5 examiners and 5 art units, placing each application in a separate examination assignment.

GONZALEZ, LUISALBERTO is the busiest examiner, with 1 pending matter. The docket calls for application-specific analysis, supported by centralized coordination of biotechnology terminology and technical evidence.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

5
Total Pending OAs
2
Non-Final OAs
3
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

1
Overdue
0
Due this week
0
Due this month
0
Due in next 60 days
0
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

2
Hard (40%)
3
Medium (60%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§101 only1 (20%)
§101 + other1 (20%)
§103 only1 (20%)
Double-patenting + other2 (40%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

4
Life Sciences
80% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
1
Mechanical / Eng
20% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

50 h
Manual time on pending OAs
10 h
Time saved (low, 20%)
18 h
Time saved (mid, 35%)
0.4 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
GONZALEZ, LUISALBERTO 1 58.5% +48.3%
YOUNGBLOOD, WILLIAM JUSTIN 1 59.5% +42.0%
SANG, HONG 1 54.9% +62.8%
EVANS, ASHLEY ELIZABETH 1 17.2% +38.5%
CLOW, LORI A 1 64.2% +28.6%

Hard Cases (2)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.

App #TitleExaminerDue in
18290575 METHODS AND MARKERS FOR DIAGNOSIS OF PARKINSON'S DISEASE EVANS, ASHLEY ELIZABETH 85d overdue
18125524 INTERROGATORY CELL-BASED ASSAYS AND USES THEREOF CLOW, LORI A —

Interview Candidates (5)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.

App #TitleExaminerDue in
18290575 METHODS AND MARKERS FOR DIAGNOSIS OF PARKINSON'S DISEASE EVANS, ASHLEY ELIZABETH 85d overdue
18711570 COMPOUNDS FOR USE IN TREATING GASTRIC CANCER GONZALEZ, LUISALBERTO —
18635905 MICROTUBULE TARGETING AGENTS YOUNGBLOOD, WILLIAM JUSTIN —
18523239 FILAMIN A BINDING PROTEINS AND USES THEREOF SANG, HONG —
18125524 INTERROGATORY CELL-BASED ASSAYS AND USES THEREOF CLOW, LORI A —

Top Art Units

Art UnitApps
1624 1
1629 1
1646 1
3687 1
1671 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18711570 COMPOUNDS FOR USE IN TREATING GASTRIC CANCER GONZALEZ, LUISALBERTO 1624 §103 Final Rejection — Pending May 17, 2024
18635905 MICROTUBULE TARGETING AGENTS YOUNGBLOOD, WILLIAM JUSTIN 1629 §102DP Final Rejection — Pending Apr 15, 2024
18523239 FILAMIN A BINDING PROTEINS AND USES THEREOF SANG, HONG 1646 §102§103§112DP Non-Final OA — Pending Nov 29, 2023
18290575 METHODS AND MARKERS FOR DIAGNOSIS OF PARKINSON'S DISEASE EVANS, ASHLEY ELIZABETH 3687 §101§102§103 Final Rejection 85d overdue Pending Nov 14, 2023
18125524 INTERROGATORY CELL-BASED ASSAYS AND USES THEREOF CLOW, LORI A 1671 §101Other Non-Final OA — Pending Mar 23, 2023

Managing BPGbio, Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does BPGbio, Inc. have?

BPGbio, Inc. has 5 pending office actions as of November 2026, spread across 5 art units and 5 examiners.

Which USPTO examiner handles the most BPGbio, Inc. applications?

Luisalberto Gonzalez has the most, with 1 of BPGbio, Inc.'s pending office actions.

What technology area are BPGbio, Inc.'s patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month